These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8357999)

  • 1. Thromboxane biosynthesis and metabolism in cardiovascular and renal disease.
    Patrono C; Patrignani P; Daví G
    J Lipid Mediat; 1993; 6(1-3):411-5. PubMed ID: 8357999
    [No Abstract]   [Full Text] [Related]  

  • 2. Alterations of renal arachidonate metabolism in chronic glomerular disease.
    Patrono C; Ciabattoni G; Simonetti BM; Pierucci A
    Adv Prostaglandin Thromboxane Leukot Res; 1986; 16():199-204. PubMed ID: 2949549
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cardiorenal interactions: clinical implication and role in pathogenesis of cardiovascular and renal diseases].
    Mukhin NA; Moiseev VS; Kobalava ZhD; Moiseev SV; Fomin VV
    Ter Arkh; 2004; 76(6):39-46. PubMed ID: 15332575
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostaglandins and vascular function.
    Weksler BB
    Circulation; 1984 Nov; 70(5 Pt 2):III63-71. PubMed ID: 6386223
    [No Abstract]   [Full Text] [Related]  

  • 5. The molecular, biochemical and human pharmacology of thromboxane A2 in renal disease.
    FitzGerald GA; Murray R; Price P; Catella F
    Adv Exp Med Biol; 1989; 259():325-60. PubMed ID: 2516412
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemical risk markers: a novel area for better prediction of renal risk?
    Stuveling EM; Bakker SJ; Hillege HL; de Jong PE; Gans RO; de Zeeuw D
    Nephrol Dial Transplant; 2005 Mar; 20(3):497-508. PubMed ID: 15735241
    [No Abstract]   [Full Text] [Related]  

  • 7. Mechanisms of eicosanoid action.
    FitzGerald GA; Murray R; Moran N; Funk C; Charman W; Clarke R; Furci L; Fitzgerald DJ
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():577-81. PubMed ID: 1825381
    [No Abstract]   [Full Text] [Related]  

  • 8. Lipid metabolism and causal pathways for cardiovascular disease in chronic kidney disease.
    van Heyningen C
    Curr Opin Lipidol; 2009 Oct; 20(5):440-1. PubMed ID: 19741339
    [No Abstract]   [Full Text] [Related]  

  • 9. Thromboxane biosynthesis and pharmacologic modulation in progressive glomerulosclerosis.
    Patrono C; Salvati P
    Am J Nephrol; 1989; 9 Suppl 1():13-6. PubMed ID: 2646922
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypertension and cardiovascular risk in chronic kidney disease patients.
    Luño J; Rodriguez-Iturbe B; Ayus JC
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S157-8. PubMed ID: 17130254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homocysteine in renal disease.
    Ducloux D; Motte G; Chalopin JM
    Clin Lab; 2000; 46(3-4):141-51. PubMed ID: 10791121
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo inhibition of thromboxane biosynthesis by hydralazine.
    Greenwald JE; Wong LK; Alexander M; Bianchine JR
    Adv Prostaglandin Thromboxane Res; 1980; 6():293-5. PubMed ID: 7386270
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dietetic effects on the prostanoid system in cardiovascular diseases].
    Markov KhM
    Vopr Pitan; 1989; (4):4-12. PubMed ID: 2510405
    [No Abstract]   [Full Text] [Related]  

  • 14. Glomerular prostanoid production is modified by plasma samples of hypertensive and diabetic patients.
    Székács B; Vajó Z; Juhász I; Vaslaki L; Nagy V
    Acta Physiol Hung; 1997-1998; 85(1):17-28. PubMed ID: 9530433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic risk factors and markers of cardiovascular and renal damage in overweight subjects.
    Bigazzi R; Bianchi S; Batini V; Guzzo D; Campese VM
    Am J Hypertens; 2006 Apr; 19(4):426-31. PubMed ID: 16580581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.
    Cleland LG; Caughey GE; James MJ; Proudman SM
    J Rheumatol; 2006 Oct; 33(10):1973-9. PubMed ID: 16881100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?
    Halushka MK; Halushka PV
    Circulation; 2002 Apr; 105(14):1620-2. PubMed ID: 11940535
    [No Abstract]   [Full Text] [Related]  

  • 18. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin.
    Evangelista V; Manarini S; Di Santo A; Capone ML; Ricciotti E; Di Francesco L; Tacconelli S; Sacchetti A; D'Angelo S; Scilimati A; Sciulli MG; Patrignani P
    Circ Res; 2006 Mar; 98(5):593-5. PubMed ID: 16484611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin.
    Pulcinelli FM; Riondino S; Celestini A; Pignatelli P; Trifirò E; Di Renzo L; Violi F
    J Thromb Haemost; 2005 Dec; 3(12):2784-9. PubMed ID: 16359516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of renal inflammatory cell infiltrate with thromboxane.
    Lim LK; Alijani MR; Helfrich GB; Foegh ML
    Transplant Proc; 1988 Apr; 20(2):258-9. PubMed ID: 3284053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.